Johnson & Johnson has eliminated a key US trial of addictive painkillers through a settlement. The company announced during the night on Wednesday that it had agreed payments totaling $ 20.4 million (18.7 million euros) from two districts in the state of Ohio.
As a result, Johnson & Johnson will not be responsible for the first US opiate process at the federal level and will not be liable. However, the company is still facing further lawsuits in the US.
The company, which manufactures a fentanyl patch and two versions of an opiate tablet, admitted no guilt. The comparison was only sought in order to avoid "the resource expenditure and the uncertainty" of a procedure. Johnson & Johnson is accused of veiling the significant search risks of its opiate-containing drugs, contributing to the rampant drug addiction and drug epidemic in the US.
Without the settlement, the trial would have started on October 21 at the federal court in Cleveland. With Mallinckrodt, Endo International and Allergan, three other pharmaceutical companies had previously prevented comparisons from reaching the dock during the trial.
Johnson & Johnson had risked doing so in August in a lawsuit in Oklahoma, where it was fined US $ 572 million for illegally marketing addictive painkillers. The company immediately announced its appointment. The OxyContin manufacturer Purdue Pharma had even been sentenced this year to a fine of 12 billion US dollars and had to file for bankruptcy.